TRex Bio, Inc. (TRXB) company profile
TRXBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 13, 2026
$10.00−0.77 (-7.15%)
Close on Nov 17, 2026Market cap $15.02MP/E –Yield –
About TRex Bio
Biological Products, (No Diagnostic Substances), SIC 2836
TRex Bio, Inc. is listed on Nasdaq under the ticker TRXB, in the SEC industry Biological Products, (No Diagnostic Substances). It is incorporated in Delaware and its fiscal year ends on December 31. Reported financials on StockData start in fiscal 2024.
Company profile
Company
- Legal name
- TRex Bio, Inc.
- Headquarters
- South San Francisco, CA
- Address
- C/O Trex Bio, Inc., 269 East Grand Avenue Suite 300
- Phone
- (650) 567-5582
- Website
- trex.bio
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
Stock & identifiers
- Ticker
- TRXB
- Exchange
- Nasdaq
- IPO date
- Oct 9, 2026
- Filer category
- <br>Emerging growth company
- SEC CIK
- 2139097
- CUSIP
- 89531N100
- ISIN
- US89531N1000
- FIGI
- BBG00SHZYM97
- Share class FIGI
- BBG00SHZYMB4
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Marion Johnston Erwin Jr. | Chief Executive Officer, Director | – |
| Ariella Kelman | Chief Medical Officer | – |
| Laura Berner | Chief Operating Officer | 168,574 |
| Brandon Hants | Chief Financial Officer | – |
| Ali Zarrin | Chief Scientific Officer | 18,111 |
| Joel S. Marcus | Director | 41,871 |
| Peter Hirth | Director | 38,202 |
| Carol Giltner Gallagher | Director | 251,471 |
| Michael Jay Ross | Director | – |
| Travis Alan Coy | Director | – |
| Julie Ann Gilmore | Director | – |
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Oct 9, 2026
- Offer price
- $14.00
- Securities offered
- 8,333,334
- Gross proceeds
- $116.67M
- Exchange
- Nasdaq
- First trading day
- Oct 9, 2026
- First-day close
- $14.000.0%
- Lock-up ends (est.)
- Apr 7, 2027
“The initial public offering price is $14.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Oct 9, 2026 | IPO | Initial public offering priced (424B4 prospectus) |
| Oct 6, 2026 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?